¹Ì±¹ÀÇ °æ±¸ °íÇüÁ¦ À§Å¹»ý»ê ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : Á¦Ç°º°, ¸ÞÄ¿´ÏÁòº°, ÃÖÁ¾ ¿ëµµº°, ±¹°¡º°, ºÎ¹®º° ¿¹Ãø(2025-2030³â)
U.S. Oral Solid Dosage Contract Manufacturing Market Size, Share & Trends Analysis Report By Product, By Mechanism (Immediate Release, Delayed Release), By End Use, By Country And Segment Forecasts, 2025 - 2030
»óǰÄÚµå : 1630996
¸®¼­Ä¡»ç : Grand View Research, Inc.
¹ßÇàÀÏ : 2024³â 12¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 100 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,950 £Ü 8,609,000
Unprintable PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,950 £Ü 10,055,000
Printable PDF (5-User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,950 £Ü 12,949,000
Printable PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¹Ì±¹ÀÇ °æ±¸ °íÇüÁ¦ À§Å¹»ý»ê ½ÃÀå ¼ºÀå°ú µ¿Çâ:

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é, ¹Ì±¹ÀÇ °æ±¸ °íÇüÁ¦ À§Å¹»ý»ê ½ÃÀå ±Ô¸ð´Â 2025³âºÎÅÍ 2030³â±îÁö CAGR 6.1%¸¦ ±â·ÏÇϸç 2030³â¿¡´Â 164¾ï 3,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ ½ÃÀåÀÇ ¼ºÀåÀº ±¹³» ÀǾàǰ ¾Æ¿ô¼Ò½ÌÀÇ Áõ°¡¿Í ±â¼ú ¹ßÀü µîÀÇ ¿äÀο¡ ±âÀÎÇÕ´Ï´Ù. ȯÀÚ Áß½ÉÀÇ Á¦Çü¿¡ ´ëÇÑ ¼ö¿ä´Â º¹¾à ¼øÀÀµµ¸¦ ³ôÀ̱⠶§¹®¿¡ ÀÇ·á ºÐ¾ß¿¡¼­ ¸Å¿ì Áß¿äÇÑ Æ®·»µå·Î ÀÚ¸® Àâ°í ÀÖ½À´Ï´Ù. ±× °á°ú, Á¦Á¶»çµéÀº »ïŰ±â ½¬¿î °æ±¸¿ë Á¦ÇüÀ» ¿ì¼±ÀûÀ¸·Î »ý»êÇϰí ÀÖ½À´Ï´Ù.

°íü °æ±¸¿ë ÀǾàǰÀÇ »ç¿ë ÆíÀǼºÀ» ³ôÀ̱â À§ÇØ Á¦¾àȸ»çµéÀº ÀǾàǰÀ» ¸¶ÀÌÅ©·Î Á¤Á¦, ¹Ì´Ï Á¤Á¦, ½ºÇÁ¸µÅ¬·¯ ĸ½¶·Î Çõ½ÅÀûÀ¸·Î ¹Ù²Ù°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¦Çü Á¢±Ù ¹æ½ÄÀº ƯÈ÷ ¾î¸°ÀÌ¿Í ³ëÀÎµé »çÀÌ¿¡¼­ Àα⸦ ²ø°í ÀÖ½À´Ï´Ù. ¸¸¼ºÁúȯ°ú °¨¿°¼º ÁúȯÀÇ È®»êÀº »õ·Î¿î Ä¡·áÁ¦¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½ÃŰ´Â ÁÖ¿ä ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. ¶ÇÇÑ, ³ëÀÎ Àα¸ÀÇ Áõ°¡´Â ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡¿¡ ±â¿©Çϰí ÀÖÀ¸¸ç, ÀÌ´Â »õ·Î¿î Ä¡·á °úÁ¤¿¡ ´ëÇÑ ¼ö¿ä¸¦ ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

±âÁ¸ ¾à¹°¿¡ ´ëÇÑ ºÎÀÛ¿ëµµ »õ·Î¿î Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 7¿ù ¸®¹öÇ® ´ëÇÐÀÌ ¹ßÇ¥ÇÑ ¿¬±¸¿¡ µû¸£¸é, ºÎÀÛ¿ëÀ¸·Î ÀÎÇÑ ÀÔ¿øÀº 2004³â 6.5%¿¡¼­ 2019³â 16.5%·Î Áõ°¡ÇÏ¿´´Ù°í ÇÕ´Ï´Ù. ±âÁ¸ Ä¡·áÁ¦¿¡ ´ëÇÑ ºÎÀÛ¿ë »ç·ÊÀÇ Áõ°¡´Â ÇâÈÄ »õ·Î¿î Ä¡·áÁ¦¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½Ãų °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸¹Àº ¹ÙÀÌ¿ÀÁ¦¾à ±â¾÷µé¿¡°Ô Çõ½Å°ú ÀÓ»ó ÁøÀÔ ¼Óµµ´Â ¸Å¿ì Áß¿äÇÑ ¿ä¼ÒÀÔ´Ï´Ù. ¼Ò±Ô¸ð ±â¾÷ ¹× Ư¼ö ¹ÙÀÌ¿À Á¦¾à ȸ»ç´Â ¾÷°è¿¡¼­ ÀÌ·¯ÇÑ Áß¿äÇÑ ¿ä±¸ »çÇ×À» ½ÇÇöÇÏ´Â µ¥ Á¡Á¡ ´õ ÀÇÁ¸Çϰí ÀÖ½À´Ï´Ù. ¸¹Àº CRO¿Í CDMO´Â ½º½º·Î¸¦ ¿ø½ºÅé ¼îÇΠȸ»ç¶ó°í È«º¸Çϰí ÀÖ½À´Ï´Ù. ¿ø½ºÅé ¼óÀº CRO°¡ ¿ø·áºÎÅÍ Á¦Çü, Ãʱ⠰³¹ß, »ó¾÷È­±îÁö ¸ðµç °ÍÀ» Á¦°øÇÏ´Â ¼­ºñ½º ¸ðµ¨ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ¼­ºñ½º¸¦ Á¦°øÇϱâ À§ÇØ CDMO´Â ƯÁ¤ ¹®Á¦ Á¦±â¿¡ ´ëÀÀÇÒ ¼ö ÀÖ´Â Æø³ÐÀº ½ÇÇö ±â¼ú°ú Àü¹®Àû ´ëÀÀ ´É·ÂÀ» °®Ãç¾ß ÇÕ´Ï´Ù.

¶ÇÇÑ, ÁÖ¿ä ±â¾÷µéÀÇ Àü·«Àû ÀÌ´Ï¼ÅÆ¼ºê°¡ Áõ°¡Çϰí ÀÖ´Â °Íµµ ¹Ì±¹ °æ±¸ °íÇüÁ¦(OSD) À§Å¹»ý»ê ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 1¿ù Catalent¿Í EthicannÀº CatalentÀÇ ±¸°­ºØÇØÁ¤(ODT) ±â¼úÀÎ Zydis¸¦ »ç¿ëÇÏ¿© EthicannÀÇ ÀÓ»ó ÀǾàǰ ÆÄÀÌÇÁ¶óÀÎÀ» °³¹ßÇϱâ À§ÇØ Á¦ÈÞ¸¦ ¸Î¾ú½À´Ï´Ù. ¶Ç ´Ù¸¥ ¿¹·Î, 2023³â 3¿ù ·ÐÀÚ´Â ºñ½ºÇÁ(Visp)ÀÇ »õ·Î¿î ÀÓ»ó ¹× »ó¾÷¿ë ÀǾàǰ »ý»ê ¶óÀÎÀÌ º»°Ý °¡µ¿¿¡ µé¾î°¬´Ù°í ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ È®ÀåÀº ȸ»çÀÇ ÀǾàǰ ¼­ºñ½º(DPS)¸¦ °­È­ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¹Ì±¹ÀÇ °æ±¸ °íÇüÁ¦ À§Å¹»ý»ê ½ÃÀå : ºÐ¼® °³¿ä

¸ñÂ÷

Á¦1Àå ºÐ¼® ¹æ¹ý¡¤¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¹Ì±¹ÀÇ °æ±¸ °íÇüÁ¦ À§Å¹»ý»ê ½ÃÀå : º¯¼ö, µ¿Çâ, ¹üÀ§

Á¦4Àå ¹Ì±¹ÀÇ °æ±¸ °íÇüÁ¦ À§Å¹»ý»ê ½ÃÀå : Á¦Ç°º° ºñÁî´Ï½º ºÐ¼®

Á¦5Àå ¹Ì±¹ÀÇ °æ±¸ °íÇüÁ¦ À§Å¹»ý»ê ½ÃÀå : ¸ÞÄ¿´ÏÁòº° ºñÁî´Ï½º ºÐ¼®

Á¦6Àå ¹Ì±¹ÀÇ °æ±¸ °íÇüÁ¦ À§Å¹»ý»ê ½ÃÀå : ÃÖÁ¾ ¿ëµµº° ºñÁî´Ï½º ºÐ¼®

Á¦7Àå °æÀï ±¸µµ

KSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

U.S. Oral Solid Dosage Contract Manufacturing Market Growth & Trends:

The U.S. oral solid dosage contract manufacturing market size is expected to reach USD 16.43 billion by 2030, registering a CAGR of 6.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growth of the market is attributed to factors such as the increasing pharmaceutical outsourcing and technological advancements in the country. The demand for patient-centric dosage forms has been increasing with time, making it a pivotal trend in the medical field, as it enhances medication adherence. Consequently, manufacturers are producing oral dosage forms that prioritize ease of swallowing.

To render solid oral drugs more user-friendly, drug sponsors are innovatively transforming drugs into micro or mini tablets and sprinkle capsules. This formulation approach is gaining popularity, especially among the pediatric and geriatric populations. The growing prevalence of chronic and infectious diseases is one of the major factors responsible for the rising demand for novel therapies. Furthermore, the growing geriatric population is contributing to the rising incidence of chronic diseases, further supporting the demand for novel treatment processes.

Adverse drug reactions to existing drugs are also contributing to the demand for novel treatment options. For instance, in July 2022, research published by the University of Liverpool stated that adverse drug reaction-related hospital admissions increased from 6.5% in 2004 to 16.5% in 2019. A rise in the number of cases involving adverse drug reactions to existing therapies is expected to boost the demand for new therapies in the future.

For many biopharmaceutical companies, innovations and speed-to-clinic factors are of critical importance. Small companies and specialty biopharmaceutical players increasingly rely upon delivering these important requirements within the industry. Many CROs and CDMOs promote themselves as one-stop-shop companies. The one-stop-shop service model is where a CRO handles everything from API to dosage form and early development to commercialization. To provide these services, a CDMO must have a wide range of enabling technologies and specialized handling capabilities to address specific problem statements.

Furthermore, increasing undertaking of strategic initiatives by key players is also expected to drive U.S. oral solid dosage (OSD) contract manufacturing market growth. For instance, in January 2023, Catalent and Ethicann collaborated to develop Ethicann's clinical drug pipeline using Catalent's orally disintegrating tablet (ODT) technology 'Zydis'. In another instance, in March 2023, Lonza announced that its new clinical and commercial drug product manufacturing line at its Visp site had become fully operational. The expansion is expected to strengthen the company's Drug Product Services (DPS) offering.

U.S. Oral Solid Dosage Contract Manufacturing Market Report Highlights:

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. U.S. Oral Solid Dosage Contract Manufacturing Market Variables, Trends, & Scope

Chapter 4. U.S. Oral Solid Dosage Contract Manufacturing Market: Product Business Analysis

Chapter 5. U.S. Oral Solid Dosage Contract Manufacturing Market: Mechanism Business Analysis

Chapter 6. U.S. Oral Solid Dosage Contract Manufacturing Market: End Use Business Analysis

Chapter 7. Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â